twotarget

Twotarget is a discontinued chemotherapy regimen, primarily used in the treatment of castration-resistant prostate cancer. The name comes from the fact that it targets two distinct biochemical pathways: androgen signaling and the PI3K/AKT/mTOR signaling pathways.

The twotarget regimen typically consists of abiraterone acetate, a CYP17 inhibitor, combined with prednisone. Abiraterone acetate was specifically designed to block the production of androgens in the body, which can fuel prostate cancer growth. Prednisone is a steroid that helps to manage the side effects associated with the use of abiraterone acetate. In some cases, the regimen may also include a PI3K/mTOR inhibitor, such as everolimus, to further target the PI3K/AKT/mTOR pathway.

Research has shown that the twotarget regimen can lead to significant improvements in overall survival and progression-free survival for patients with castration-resistant prostate cancer. However, it also carries potential side effects, including hypertension, hypokalemia, and adrenal insufficiency, among others.

Twotarget has been approved by the United States Food and Drug Administration (FDA) in 2013 for use in combination with prednisone for the treatment of patients with castration-resistant prostate cancer who have previously received docetaxel. However, due to concerns about the frequency and severity of certain side effects, its use has been limited. Today, the twotarget regimen is mostly used as an alternative or in conjunction with other treatments in specific cases.